Published in J Clin Oncol on August 20, 2006
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann Oncol (2010) 1.63
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med (2009) 1.62
Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer (2008) 1.62
Relationship between deficits in overall quality of life and non-small-cell lung cancer survival. J Clin Oncol (2012) 1.33
Treatment of advanced non small cell lung cancer. J Thorac Dis (2011) 1.32
Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol (2012) 1.27
Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol (2009) 1.26
Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget (2011) 1.24
Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol (2009) 1.06
Lung cancer: Biology and treatment options. Biochim Biophys Acta (2015) 1.02
Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist (2012) 0.98
Time to deterioration in quality of life score as a modality of longitudinal analysis in patients with breast cancer. Oncologist (2011) 0.97
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol (2009) 0.93
Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biologics (2007) 0.93
Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review. Ann Thorac Med (2013) 0.92
Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach. Curr Oncol (2010) 0.92
Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Med (2012) 0.89
Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland. Contemp Oncol (Pozn) (2012) 0.88
The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement. Curr Oncol (2009) 0.86
Health-related quality of life questionnaires in lung cancer trials: a systematic literature review. Health Econ Rev (2013) 0.86
Biomarkers in lung cancer: from early detection to novel therapeutics and decision making. Biomark Med (2008) 0.86
Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy. Clinicoecon Outcomes Res (2012) 0.85
Tumor epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer. Oncologist (2011) 0.85
Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer. Oncol Lett (2012) 0.85
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC Cancer (2011) 0.85
Second-Line Therapy for Advanced NSCLC. Oncologist (2013) 0.84
Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer. J Cancer Res Clin Oncol (2015) 0.83
Mind-mapping for lung cancer: towards a personalized therapeutics approach. Adv Ther (2011) 0.83
Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells. Invest New Drugs (2012) 0.83
First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view. BMC Proc (2008) 0.83
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer. J Clin Oncol (2007) 0.82
What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer. Support Care Cancer (2015) 0.82
miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway. Int J Oncol (2016) 0.82
The Value of MicroRNA-155 as a Prognostic Factor for Survival in Non-Small Cell Lung Cancer: A Meta-Analysis. PLoS One (2015) 0.81
Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial. Cancer Res Treat (2014) 0.80
Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients. Drugs (2012) 0.80
Erlotinib for elderly patients with non-small-cell lung cancer: Subset analysis from a population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group. Mol Clin Oncol (2013) 0.80
Baseline health-related quality of life and 10-year all-cause mortality among 1739 Chinese adults. PLoS One (2014) 0.79
Prolonged response to first-line erlotinib for advanced lung adenocarcinoma. J Exp Clin Cancer Res (2008) 0.79
The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis. Medicine (Baltimore) (2016) 0.79
Rest/activity rhythm is related to the coexistence of pain and sleep disturbance among advanced cancer patients with pain. Support Care Cancer (2013) 0.79
Epidermal growth factor receptor exon 20 mutation increased in post-chemotherapy patients with non-small cell lung cancer detected with patients' blood samples. Transl Oncol (2013) 0.79
[Implications of modern anticancer therapies for palliative care concepts]. Schmerz (2010) 0.79
Review of the treatment of metastatic non small cell lung carcinoma: A practical approach. World J Clin Oncol (2011) 0.77
[Molecular diagnostics in lung carcinoma for therapy stratification]. Pathologe (2010) 0.77
Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. P T (2009) 0.77
The Evolving Role of Maintenance Therapy Using Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) in the Management of Advanced Non-Small-Cell Lung Cancer. Clin Med Insights Oncol (2012) 0.77
Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. Support Care Cancer (2015) 0.76
Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes. Eur J Cancer (2016) 0.75
Role of epidermal growth factor receptor in lung cancer and targeted therapies. Am J Cancer Res (2017) 0.75
Palliative chemotherapy: oxymoron or misunderstanding? BMC Palliat Care (2016) 0.75
Epidermal growth factor receptor tyrosine kinase inhibitors for elderly patients with advanced non-small cell lung cancer. Curr Gerontol Geriatr Res (2010) 0.75
Surviving with lung cancer: medication-taking and oral targeted therapy. Geriatr Nurs (2014) 0.75
Erlotinib-induced complete response in a patient with epidermal growth factor receptor wild-type lung adenocarcinoma after chemotherapy failure: a case report. J Med Case Rep (2014) 0.75
Does erlotinib improve symptoms in patients with lung cancer? Nat Clin Pract Oncol (2007) 0.75
Systems Chronotherapeutics. Pharmacol Rev (2017) 0.75
A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer. Oncol Rep (2012) 0.75
Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer. Lung Cancer (Auckl) (2010) 0.75
The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011. Einstein (Sao Paulo) (2015) 0.75
Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan. Int J Clin Oncol (2011) 0.75
["Targeted Therapies" in NSCLC - present and future]. Wien Med Wochenschr (2007) 0.75
Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. ESMO Open (2017) 0.75
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report. Int Med Case Rep J (2017) 0.75
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
Cetuximab for the treatment of colorectal cancer. N Engl J Med (2007) 13.39
Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med (2005) 13.01
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol (2004) 12.89
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med (2005) 10.58
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet (2009) 8.73
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 8.21
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol (2009) 7.80
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol (2008) 7.35
Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol (2002) 6.51
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol (2003) 5.84
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (2009) 5.82
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med (2006) 5.10
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol (2011) 5.06
Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med (2013) 4.64
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol (2006) 4.58
Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med (2005) 4.48
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol (2009) 4.27
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol (2010) 4.19
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol (2008) 3.97
Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol (2008) 3.95
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist (2009) 3.92
Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res (2002) 3.68
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol (2011) 3.51
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol (2008) 3.49
Non-small-cell lung cancer. Lancet (2011) 3.45
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol (2008) 3.40
Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet (2009) 3.38
Texas lifestyle limits transmission of dengue virus. Emerg Infect Dis (2003) 3.34
Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, and abnormal head size. J Med Genet (2009) 3.33
Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res (2003) 3.30
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol (2011) 3.24
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res (2007) 3.18
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.13
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol (2007) 2.93
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol (2011) 2.92
Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci U S A (2009) 2.84
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol (2005) 2.76
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol (2006) 2.74
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol (2011) 2.69
Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol (2005) 2.41
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med (2013) 2.38
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol (2005) 2.36
K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer (2006) 2.29
The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol (2009) 2.29
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol (2014) 2.25
Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol (2008) 2.20
Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol (2005) 2.20
HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist (2005) 2.17
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst (2009) 2.16
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol (2007) 2.15
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer (2006) 2.14
Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol (2007) 2.10
Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol (2009) 2.08
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol (2010) 2.05
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol (2009) 2.04
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol (2007) 2.03
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncol (2013) 1.99
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol (2007) 1.93
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol (2008) 1.92
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst (2005) 1.90
EGFR mutations and lung cancer. Annu Rev Pathol (2011) 1.89